Journals / Interdisciplinary Medical Journal / 2021 / Cilt: 12 - Sayı: 43

Evaluation of Time in Therapeutic Range in Patients with Cerebrovascular Disease Receiving Treatment with Warfarin

Varfarin Tedavisi Alan Serebrovasküler Hastalığı Olan Hastalarda Terapötik Aralıkta Olma Oranlarının Değerlendirilmesi

Pages
88–93
Publication Date
2021-08-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Regular monitoring of stroke patients using warfarin will be beneficial in terms of informing patients, providing optimal anticoagulation and preventing complications.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The efficacy of warfarin therapy correlates with the Time in Therapeutic Range (TTR).
📊
Key Findings & Data:This study aimed to investigate the efficacy and target achievement rates in patients using warfarin who were followed up in stroke outpatient clinics.Methods: In this study, 103 patients who had been under warfarin treatment were retrospectively evaluated.
💡
Conclusion & Impact:Regular monitoring of stroke patients using warfarin will be beneficial in terms of informing patients, providing optimal anticoagulation and preventing complications.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Varfarin · Etkinlik · Antikoagulasyon

Abstract

Objective: The efficacy of warfarin therapy correlates with the Time in Therapeutic Range (TTR). This study aimed to investigate the efficacy and target achievement rates in patients using warfarin who were followed up in stroke outpatient clinics.Methods: In this study, 103 patients who had been under warfarin treatment were retrospectively evaluated. Duration and indications for warfarin use, thrombotic or hemorrhagic complications were recorded. Target INR value was 3.0-3.5 in patients with mechanical valves and 2.0-3.0 in those using warfarin for other indications.Results: In this study, 103 patients with a mean age of 67.14±14.19, 47 men and 56 women, were included. Indications for warfarin use, respectively, were non-valvular atrial fibrillation (AF) in 61.6% of the patients, akinetic/hypokinetic segment on echocardiography (ECHO) in 12.62%, thrombophilia in 8.74%, metallic prosthetic valve in 3.88%, frequent transient ischemic attacks in 6.79%, a hypokinetic segment on ECHO with atrial fibrillation in 5.82% and vertebral artery dissection in 0.87%. 46.8% of the patients were determined to be in good control, with a mean TTR of 64.09%; also, TTR was 100% in 36.8% of them. Minor/major hemorrhagic event was noted in 10 patients (9.70%), two of whom had an intracerebral hemorrhage.Conclusion: The mean TTR value detected in this study is considerably higher than the rate reported in our country. Findings of this study suggest that close monitoring is paramount of importance and vital in patients with stroke. Regular monitoring of stroke patients using warfarin will be beneficial in terms of informing patients, providing optimal anticoagulation and preventing complications.

Özet

Amaç: Varfarin tedavisinin etkinliği, Terapötik Aralıkta Olma Zamanı (TTR) ile doğrudan ilişkilidir. Bu çalışmada, inme polikliniğinde izlenen warfarin kullanan hastalarda etkinlik ve hedefe ulaşma oranlarının belirlenmesi amaçlanmıştır.Yöntem: İnme polikliniğinde izlenen, varfarin kullanan 103 hasta, retrospektif olarak değerlendirildi. Varfarin kullanım süreleri, ve endikasyonlarıyla trombotik veya hemorajik komplikasyonları kaydedildi. Hedef INR değeri mekanik kapaklı hastalarda 3.0-3.5, diğer endikasyonlar için 2.0-3.0 arasında belirlendi.Bulgular: Çalışmaya 47’si erkek 56’sı kadın olmak üzere, ortalama yaşları 67.14 ± 14.19 olan 103 hasta dahil edildi.Varfarin kullanım endikasyonları sırasıyla hastaların %61,6’sında non-valvular atrial fibrilasyon, %12.62’sinde eko kardiyografide (EKO) akinetik/hipokinetik alan, %8.74’ünde trombofili, %3.88’inde metalik protez kapak, %6.79’unda sık geçici iskemik ataklar, %5.82’sinde atrial fibrilasyonla birlikte EKO’da hipokinetik alan ve % 0.87’sinde vertebral arter diseksiyonuydu. Hastaların %46.8’inin iyi kontrolde olduğu, ortalama TTR’nin %64.09 olduğu saptandı; ayrıca, TTR %36.8’inde %100 idi. İkisinde intraserebral kanama olan 10 hastada (%9.70) minör/majör hemorajik olay kaydedildi.Sonuç: Bu çalışmada saptanan ortalama TTR değeri, ülkemizde bildirilen orandan oldukça yüksektir. Çalışma bulgularımız, yakın izlemin inmeli hastalarda çok önemli ve hayati olduğunu göstermektedir. Varfarin kullanan inme hastalarının düzenli takibinin ve hastaları bilgilendirmenin optimal antikoagülasyon sağlanmasına ve komplikasyonları önlemeye yardımcı olacağına kanısındayız.

🔖

Cite This Article

EŞKUT, N., TAMER, P., KÜSBECİ, Ö. Y., ATAÇ, C., İNCİ, İ. (2021). Evaluation of Time in Therapeutic Range in Patients with Cerebrovascular Disease Receiving Treatment with Warfarin. Interdisciplinary Medical Journal, Cilt: 12 - Sayı: 43, 88–93. https://ajindex.com/articles/887569

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Sacco RL, Adams R, Albers G, et al.; AHA; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke. 2006;37(2):577-617. https://doi.org/10.1161/01.STR.0000199147.30016.74.
  2. Palacio S, Hart RG. Neurologic manifestations of cardiogenic embolism: an update. Neurol Clin. 2002;20(1):179-193, vii. https://doi.org/10.1016/s0733-8619(03)00058-6.
  3. Schievink WI, Mokri B, O’Fallon WM. Recurrent spontaneous cervical-artery dissection. N Engl J Med. 1994;330(6):393-397. https://doi.org/10.1056/NEJM199402103300604. Kasner SE. CADISS: a feasibility trial that answered its question. Lancet Neurol. 2015;14(4):342-343. https://doi.org/10.1016/S1474-4422(14)70271-6.
  4. Ferro JM, Canhão P, Bousser MG, et al; ISCVT Investigators. Cerebral vein and dural sinus thrombosis in elderly patients. Stroke. 2005;36(9):1927-1932. https://doi.org/10.1161/01.STR.0000177894.05495.54.
  5. Ferro JM, Canhão P, Stam J, et al; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664-670. https://doi.org/10.1161/01.STR.0000117571.76197.26.
  6. Natarajan S, Ponde CK, Rajani RM, et al. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients. Pharmacol Rep. 2013;65(5):1375-1382. https://doi.org/10.1016/s1734-1140(13)71496-8.
  7. Joffe HV, Xu R, Johnson FB, et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost. 2004;91(6):1123-1128. https://doi.org/10.1160/TH04-02-0083.
  8. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095-1106. https://doi.org/10.1001/archinte.165.10.1095.
  9. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6):160S-198S. https://doi.org/10.1378/chest.08-0670.
  10. P Caldeira D, Cruz I, Morgado G, et al. Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study. BMC Res Notes. 2014;7:891. https://doi.org/10.1186/1756-0500-7-891. Odén A, Fahlén M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical